News Center
News Type
Qingfeng Pharmaceutical Partners with Kexing Biopharm to Globalize Olaparib for Cancer Patients Worldwide
On the afternoon of April 28, 2024, Qingfeng Pharmaceutical Group's subsidiary, Kvvit Pharmaceuticals, signed a licensing agreement with Kexing Biopharm (688136.SH) for the international commercialization of Olaparib tablets.
Qingfeng Pharmaceutical Showcases Oranti® Citrus Aurantium Total Flavonoid Tablets at the Shanghai Cooperation Organization Traditional Medicine Forum
On November 30, 2023, the Shanghai Cooperation Organization Traditional Medicine Forum kicked off in the Traditional Chinese Medicine Science and Technology Innovation City in Nanchang, China. At the invitation of the forum organizers, Qingfeng Pharmaceutical set up an exhibition booth in the Jiangxi Pavilion, where the company highlighted its major innovations, including Aurantii Fructus Immaturus Total Flavonoids tablet.
The application for the NDA of the new anti-influenza drug GP681 tablets was accepted by NMPA
On November 24, the official website of the Center for Drug Evaluation (CDE) of the NMPA announced that the marketing application for GP681 tablets, a Class 1 innovative chemical drug registered and submitted by Qingfeng Pharmaceutical/Kerui Pharmaceuticals, a subsidiary of Qingfeng Pharmaceutical, was accepted by the NMPA and received a "Notice of Acceptance".
Our Company Donates to the Qianqing Volunteer Association in Zhanggong District
On the morning of October 31, 2023, Group Vice President Chen Lin visited the Qianqing Volunteer Association in Zhanggong District (Zhanggong District Gansu Youth Assault Team) to make a donation on behalf of the company.
Great news! Qingfeng Pharmaceutical's Enzalutamide API and Soft Capsules are approved for marketing in the United States
On September 26, the enzalutamide API and soft capsule developed by Qingfeng Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group, were approved for marketing by the U.S. Food and Drug Administration (FDA).
Big news! Enzalutamide API successfully passed FDA on-site audit
From August 21 to 25, 2023, the U.S. Food and Drug Administration (FDA) conducted a five-day on-site audit of Qingfeng Pharmaceutical's enzalutamide API and the company's overall production quality management system. FDA Inspector Ms. Michele Glendenning gave a formal opinion that the inspection passed.
